Data Presented At The 5th Joint Triennial Congress Of ECTRIMS And ACTRIMS ... TheStreet.com (press release) ... marketed products, TYSABRI ® (natalizumab), AVONEX ® (interferon beta-1a) and FAMPYRA ® (prolonged-release fampridine), as well as two late-stage investigational compounds, oral BG-12 (dimethyl fumarate) and daclizumab high-yield process (DAC HYP). ... Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS ... |
